Creative Medical Health Inc. Files Patent on Multiple Sclerosis Stem Cell Therapy

Creative Medical Health has announced filing of intellectual property covering the use of its proprietary mesenchymal stem cell-based product for treatment for autoimmune diseases, with multiple sclerosis being the first disease in which the product will be clinically assessed. The patent covers various modifications and cell types that are used to specifically stop the immunological processes that cause inflammation in the nervous system, which leads to the pathology seen in multiple sclerosis. Multiple sclerosis affects approximately 23 million patients, with a global market for disease-modifying products that reached nearly $10.9 billion in 2013. This is estimated to grow to nearly $14.2 billion by 2018.

“The core belief of Creative Medical Health is to empower the body to heal itself through mechanisms that are natural to the body, but for whatever reason became deregulated,” said Dr Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at University of Utah and Board Member of Creative Medical Health. “In the case of the recently filed patent, we are leveraging the innate ability of mesenchymal stem cells to stop pathological immune attack on the nervous system and to induce T regulatory cells, a type of cell that protects the body from autoimmune attack.”

Creative Medical Health has developed a broad range of biotechnology and bionutraceutical products that function through augmenting the body’s endogenous regenerative mechanisms.

“At Creative Medical Health we take a very aggressive approach to intellectual property, having one issued patent covering stem cells for erectile dysfunction and 11 patent applications at the various stages of the approval process. The filing of today’s patent increases our IP footprint and allows for our extension into the area of multiple sclerosis, a disease for which no cure currently exists,” said Timothy Warbington, CEO of Creative Medical Health.